Stroke prevention in atrial fibrillation: a systematic review
Related Experiment Video
Updated: Apr 12, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Gregory Y H Lip1, Deirdre A Lane2
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom2Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Insights
Oral anticoagulation significantly reduces stroke risk in atrial fibrillation (AF). Patients with AF and at least one risk factor should be offered oral anticoagulation for effective stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases mortality, morbidity, and the risk of stroke.
- AF-related strokes result in higher mortality, disability, and prolonged hospital stays compared to non-AF strokes.
Purpose of the Study:
- To review current concepts and recent advancements in stroke prevention for patients with AF.
- To provide practical management suggestions for stroke risk reduction in AF.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE up to March 11, 2015.
- Studies focused on atrial fibrillation, stroke, bleeding risks, and prevention strategies.
Main Results:
- Anticoagulant therapy, including vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs), effectively reduces stroke risk in AF.
- Oral anticoagulation (OAC) is recommended for AF patients with a CHA2DS2-VASc score of 1 or higher (excluding women with a score of 1 solely due to sex).
- Assessing and managing bleeding risk factors, such as controlling blood pressure and avoiding unnecessary medications, is crucial alongside OAC therapy.
Conclusions:
- Stroke prevention is a critical aspect of AF management, regardless of rate or rhythm control.
- All AF patients with one or more stroke risk factors should be considered for oral anticoagulation therapy.
Importance:
Atrial fibrillation (AF) is associated with an increase in mortality and morbidity, with a substantial increase in stroke and systemic thromboembolism. Strokes related to AF are associated with higher mortality, greater disability, longer hospital stays, and lower chance of being discharged home than strokes unrelated to AF.
Objective:
To provide an overview of current concepts and recent developments in stroke prevention in AF, with suggestions for practical management.
Evidence Review:
A comprehensive structured literature search was performed using MEDLINE for studies published through March 11, 2015, that reported on AF and stroke, bleeding risk factors, and stroke prevention.
Findings:
The risk of stroke in AF is reduced by anticoagulant therapy. Thromboprophylaxis can be obtained with vitamin K antagonists (VKA, eg, warfarin) or a non-VKA oral anticoagulant (NOAC). Major guidelines emphasize the important role of oral anticoagulation (OAC) for effective stroke prevention in AF. Initially, clinicians should identify low-risk AF patients who do not require antithrombotic therapy (ie, CHA2DS2-VASc score, 0 for men; 1 for women). Subsequently, patients with at least 1 stroke risk factor (except when the only risk is being a woman) should be offered OAC. A patient's individual risk of bleeding from antithrombotic therapy should be assessed, and modifiable risk factors for bleeding should be addressed (blood pressure control, discontinuing unnecessary medications such as aspirin or nonsteroidal anti-inflammatory drugs). The international normalized ratio should be tightly controlled for patients receiving VKAs.
Conclusions And Relevance:
Stroke prevention is central to the management of AF, irrespective of a rate or rhythm control strategy. Following the initial focus on identifying low-risk patients, all others with 1 or more stroke risk factors should be offered OAC.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:25Dysrhythmias VI: Management of Dysrhythmias
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care